SCHEMBL4491535

SCHEMBL4491535

Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 4/20 0.56
GSK3B P49841 2/20 0.55
JAK2 O60674 2/20 0.54
PDPK1 O15530 9/20 0.53
ABL1 P00519 3/20 0.50
BCR P11274 2/20 0.50
SCN5A Q14524 1/20 0.49
SCN9A Q15858 1/20 0.49
ROCK1 Q13464 3/20 0.49
KDR P35968 2/20 0.49
DAPK3 O43293 1/20 0.49
PRKD3 O94806 1/20 0.49
MAP4K4 O95819 1/20 0.49
PAK4 O96013 1/20 0.49
NTRK1 P04629 1/20 0.49
LCK P06239 1/20 0.49
CSF1R P07333 1/20 0.49
RET P07949 1/20 0.49
IGF1R P08069 1/20 0.49
MET P08581 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13525283 0.85 JAK2 (0.51) SGK1JAK2PDPK1ABL1BCR
SCHEMBL4487734 0.83 JAK2 (0.64) SGK1GSK3BJAK2PDPK1ABL1
SCHEMBL4494073 0.82 JAK2 (0.72) SGK1GSK3BJAK2PDPK1ABL1
SCHEMBL13524510 0.82 PDPK1 (0.50) SGK1JAK2PDPK1ABL1SCN5A
SCHEMBL4481983 0.82 HDAC6 (0.58) SGK1GSK3BJAK2PDPK1ABL1
SCHEMBL31032784 0.82 PDPK1 (0.60) SGK1JAK2PDPK1ABL1BCR
SCHEMBL220002 0.82 PDPK1 (0.60) SGK1JAK2PDPK1ABL1BCR
SCHEMBL31032783 0.82 PDPK1 (0.60) SGK1JAK2PDPK1ABL1BCR
SCHEMBL4497038 0.78 PDPK1 (0.71) SGK1GSK3BJAK2PDPK1ABL1
SCHEMBL6478350 0.78 JAK2 (0.65) SGK1GSK3BJAK2PDPK1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP disclosed
US-7632854-B2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2009-12-15 US disclosed
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2006-05-18 US disclosed
EP-1506176-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-02-16 EP disclosed
WO-2003097610-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K15, MAP3K3, MAP3K20 SGK1 229/4885GSK3B 96/4885JAK2 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.